Review



mouse hprt1 transcripts  (Integrated DNA Technologies)


Bioz Verified Symbol Integrated DNA Technologies is a verified supplier
Bioz Manufacturer Symbol Integrated DNA Technologies manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Integrated DNA Technologies mouse hprt1 transcripts
    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to <t>Hprt1)</t> in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Mouse Hprt1 Transcripts, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 95/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse hprt1 transcripts/product/Integrated DNA Technologies
    Average 95 stars, based on 4 article reviews
    mouse hprt1 transcripts - by Bioz Stars, 2026-05
    95/100 stars

    Images

    1) Product Images from "Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS"

    Article Title: Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS

    Journal: Nucleic Acids Research

    doi: 10.1093/nar/gkac037

    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to Hprt1) in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Figure Legend Snippet: Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to Hprt1) in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.

    Techniques Used: Expressing, Whisker Assay, Concentration Assay



    Similar Products

    mouse hprt1 transcripts  (Integrated DNA Technologies)
    95
    Integrated DNA Technologies mouse hprt1 transcripts
    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to <t>Hprt1)</t> in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Mouse Hprt1 Transcripts, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse hprt1 transcripts/product/Integrated DNA Technologies
    Average 95 stars, based on 1 article reviews
    mouse hprt1 transcripts - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    trueguide positive crrna control  (Thermo Fisher)
    90
    Thermo Fisher trueguide positive crrna control
    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to <t>Hprt1)</t> in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Trueguide Positive Crrna Control, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trueguide positive crrna control/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    trueguide positive crrna control - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    trueguide positive negative sgrna crrna controls  (Thermo Fisher)
    90
    Thermo Fisher trueguide positive negative sgrna crrna controls
    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to <t>Hprt1)</t> in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Trueguide Positive Negative Sgrna Crrna Controls, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trueguide positive negative sgrna crrna controls/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    trueguide positive negative sgrna crrna controls - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    predesigned alt r crispr cas9 human hprt positive control crrna  (Danaher Inc)
    86
    Danaher Inc predesigned alt r crispr cas9 human hprt positive control crrna
    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to <t>Hprt1)</t> in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Predesigned Alt R Crispr Cas9 Human Hprt Positive Control Crrna, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/predesigned alt r crispr cas9 human hprt positive control crrna/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    predesigned alt r crispr cas9 human hprt positive control crrna - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    mouse genome editing  (Danaher Inc)
    95
    Danaher Inc mouse genome editing
    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to <t>Hprt1)</t> in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Mouse Genome Editing, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse genome editing/product/Danaher Inc
    Average 95 stars, based on 1 article reviews
    mouse genome editing - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    alt r crispr cas9 system  (Danaher Inc)
    95
    Danaher Inc alt r crispr cas9 system
    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to <t>Hprt1)</t> in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Alt R Crispr Cas9 System, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/alt r crispr cas9 system/product/Danaher Inc
    Average 95 stars, based on 1 article reviews
    alt r crispr cas9 system - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    sgrnas, spcas9 protein, positive control crrna lbcas12a  (Synthego Inc)
    90
    Synthego Inc sgrnas, spcas9 protein, positive control crrna lbcas12a
    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to <t>Hprt1)</t> in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Sgrnas, Spcas9 Protein, Positive Control Crrna Lbcas12a, supplied by Synthego Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sgrnas, spcas9 protein, positive control crrna lbcas12a/product/Synthego Inc
    Average 90 stars, based on 1 article reviews
    sgrnas, spcas9 protein, positive control crrna lbcas12a - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    positive control crrna lbcas12a  (Synthego Inc)
    90
    Synthego Inc positive control crrna lbcas12a
    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to <t>Hprt1)</t> in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.
    Positive Control Crrna Lbcas12a, supplied by Synthego Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/positive control crrna lbcas12a/product/Synthego Inc
    Average 90 stars, based on 1 article reviews
    positive control crrna lbcas12a - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    predesigned alt r crispr cas9 hprt positive control crrna  (Integrated DNA Technologies)
    99
    Integrated DNA Technologies predesigned alt r crispr cas9 hprt positive control crrna
    Step 1: iPSCs are grown to 60-80% confluency. Step 2: The ribonucleoprotein complex (RNP) consisting of <t>crRNA:</t> tracrRNA duplex and <t>Cas9</t> protein is formed and transfected within the small clusters of iPSC cells using Lipofectamine Stem Transfection Reagent (Step 3) . Step 4: Following 48 hours of incubation, positively transfected cells are single-cell sorted in a rich environment containing StemFlex medium and CloneR supplement in wells coated with Laminin. Step 5: Single-cells are grown for 10-14 days until they form a homogeneous single-cell clone and reach sufficient confluency for expansion. Step 6: A portion of the clones are selected for detection and confirmation of the desired mutations (e.g., Sanger sequencing, western blotting) and the remainder utilised for follow-up phenotyping experiments (Step 7) . Figure created with BioRender.com.
    Predesigned Alt R Crispr Cas9 Hprt Positive Control Crrna, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/predesigned alt r crispr cas9 hprt positive control crrna/product/Integrated DNA Technologies
    Average 99 stars, based on 1 article reviews
    predesigned alt r crispr cas9 hprt positive control crrna - by Bioz Stars, 2026-05
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to Hprt1) in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.

    Journal: Nucleic Acids Research

    Article Title: Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS

    doi: 10.1093/nar/gkac037

    Figure Lengend Snippet: Oligonucleotides with chimeric PN-containing backbones have improved potency and durability in CNS. ( A ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 7, D7). Relative Malat1 expression (normalized to Hprt1) in spinal cord (left) and cortex (right) one-week post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue) at the indicated dose. Data are presented as box and whisker plots with box from min to max with data from individual mice shown, n = 8 * P < 0.05, ** P < 0.01, *** P < 0.001 mixed-effects model with multiple comparisons. ( B ) Schematic representation of dosing regimen with black arrow indicating administration of ICV dose (day 0, D0) and blue arrow indicating day of analysis (day 28, D28). Relative Malat1 expression (normalized to Hprt1) in spinal cord (top left) and cortex (top right) 4 weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Concentration of oligonucleotide detected in spinal cord (bottom left) and cortex (bottom right) 4-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 4, **** P < 0.0001 one-way ANOVA with multiple comparisons. ( C ) Schematic representation of dosing regimen with black arrow indicating administration of intracerebroventricular dose (day 0, D0) and blue arrow indicating day of analysis (day 70, D70). Relative Malat1 expression (normalized to Hprt1) in the indicated tissue in CNS 10-weeks post treatment with PBS (beige), stereopure PS oligonucleotide (Malat1-200, light blue) or chimeric PN containing oligonucleotide (Malat1-244, navy blue). Data are presented as in panel A, n = 3 one-way ANOVA with multiple comparisons. Red asterisks show comparison of MALAT1-244 to PBS; blue asterisks MALAT1-244 to MALAT1-200.

    Article Snippet: Mouse Hprt1 transcripts were quantified with the following primers: forward primer: CAA ACT TTG CTT TCC CTG GTT; reverse primer: TGG CCT GTA TCC AAC ACT TC; probe sequence:/5HEX/AC CAG CAA G/Zen/C TTG CAA CCT TAA CC/3IABkFQ/ (Integrated DNA Technologies).

    Techniques: Expressing, Whisker Assay, Concentration Assay

    Step 1: iPSCs are grown to 60-80% confluency. Step 2: The ribonucleoprotein complex (RNP) consisting of crRNA: tracrRNA duplex and Cas9 protein is formed and transfected within the small clusters of iPSC cells using Lipofectamine Stem Transfection Reagent (Step 3) . Step 4: Following 48 hours of incubation, positively transfected cells are single-cell sorted in a rich environment containing StemFlex medium and CloneR supplement in wells coated with Laminin. Step 5: Single-cells are grown for 10-14 days until they form a homogeneous single-cell clone and reach sufficient confluency for expansion. Step 6: A portion of the clones are selected for detection and confirmation of the desired mutations (e.g., Sanger sequencing, western blotting) and the remainder utilised for follow-up phenotyping experiments (Step 7) . Figure created with BioRender.com.

    Journal: bioRxiv

    Article Title: An Efficient CRISPR-Cas9 DNA Editing Methodology Applicable for iPSC Disease Modelling

    doi: 10.1101/2022.04.12.488094

    Figure Lengend Snippet: Step 1: iPSCs are grown to 60-80% confluency. Step 2: The ribonucleoprotein complex (RNP) consisting of crRNA: tracrRNA duplex and Cas9 protein is formed and transfected within the small clusters of iPSC cells using Lipofectamine Stem Transfection Reagent (Step 3) . Step 4: Following 48 hours of incubation, positively transfected cells are single-cell sorted in a rich environment containing StemFlex medium and CloneR supplement in wells coated with Laminin. Step 5: Single-cells are grown for 10-14 days until they form a homogeneous single-cell clone and reach sufficient confluency for expansion. Step 6: A portion of the clones are selected for detection and confirmation of the desired mutations (e.g., Sanger sequencing, western blotting) and the remainder utilised for follow-up phenotyping experiments (Step 7) . Figure created with BioRender.com.

    Article Snippet: Predesigned Alt-R CRISPR-Cas9 HPRT Positive Control crRNA (Integrated DNA Technologies, Cat#1079132) was also purchased to target intron 6-7 of the human Hypoxanthine Phosphoribosyltransferase 1 ( HPRT ) gene.

    Techniques: Transfection, Incubation, Clone Assay, Sequencing, Western Blot